SNIPR Biome, a pioneer in the development CRISPR-Cas armed phages (CAPs) to prevent and treat bacterial infections, announced today that it has received ...
The status is based on preclinical data and data from an ongoing phase 1/2 study for BNT324/DB-1311; preliminary phase 1/2 clinical data showed anti-tu...
Mika Health, a global digital therapeutics developer specializing in meeting the needs of cancer patients, in collaboration with AstraZenecaand Daiichi S...
Laboratory of Prof. Andrea Alimonti at IOR (Institute of Oncology Research, Bellinzona, Switzerland) and Macomics to bring together expertise on myeloi...
Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of nov...
Alvotech a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz P...
LIXTE Biotechnology Holdings, Inc. a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer I...
-Logix Biosciences, a biopharmaceutical company focused on the discovery and development of a pipeline of precision therapeutics and companion diagnostic...
The Wyss Center for Bio and Neuroengineering in Geneva and Dandelion Science are excited to announce a partnership focused on a cutting-edge generat...
Repare Therapeutics , a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camons...
Vision is to establish a leading ADC developer to treat high unmet need diseases such as cancer. Founded by the team that founded and sold Emergence T...
New CL2 wet lab purpose-built facilities delivered by Kadans Science Partner will support MediMab Biotherapeutics to identify first-in-class immuno-oncol...
Technology transfer will strengthen South Africa’s pharmaceutical sovereignty and drastically reduce production costs, thus improving affordability...
START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological p...
© 2024 Biopharma Boardroom. All Rights Reserved.
